Int J Med Sci 2008; 5(5):285-291. doi:10.7150/ijms.5.285 This issue Cite

Research Paper

EGFR Expression in Gallbladder Carcinoma in North America

Matthew Kaufman1 ✉, Bhoomi Mehrotra1, Sewanti Limaye1, Sherrie White2, Alexander Fuchs1, Yehuda Lebowicz1, Sandy Nissel-Horowitz1, Adrienne Thomas1

1. Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
2. Hartford Hospital, Hartford, CT, USA

Citation:
Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A. EGFR Expression in Gallbladder Carcinoma in North America. Int J Med Sci 2008; 5(5):285-291. doi:10.7150/ijms.5.285. https://www.medsci.org/v05p0285.htm
Other styles

File import instruction

Abstract

BACKGROUND: Increased epidermal growth factor receptor (EGF receptor) expression has been noted in various cancers and has become a useful target for therapeutic interventions. Small studies from Asia and Australia have demonstrated EGFR over-expression in gallbladder cancer. We sought to evaluate the expression of EGFR in a series of 16 gallbladder cancer patients from North America.

METHODS: Using tumor registry data, we identified 16 patients diagnosed with gall bladder carcinoma at our medical center between the years of 1998 and 2005. We performed a retrospective review of these patients' charts, obtained cell blocks from pathology archives and stained for EGFR and Her2/neu.

RESULTS: Fifteen of sixteen patients were noted to over-express EGFR. Three were determined 1+, nine were 2+ and three were 3+. Eight patients had poorly differentiated adenocarcinoma, six had moderately differentiated and two had well-differentiated tumors. In this small series, there was a trend toward shorter survival and more poorly differentiated tumors in patients with greater intensity of EGFR expression. One patient was EGFR negative but 3+ for erb-2/Her 2-neu expression. No patient co-expressed EGFR and Her-2-neu. Median survival of patients in this series was 17 months.

CONCLUSION: In view of our observations confirming the over-expression of EGFR in our patient population in North America, and the recent success of EGFR targeted therapies in other solid tumors that over-express EGFR, it may now be appropriate to evaluate agents targeting this pathway either as single agents or in combination with standard chemotherapy.

Keywords: gallbladder cancer, endothelial growth factor receptor (EGFR), differentiation, survival, her-2-neu


Citation styles

APA
Kaufman, M., Mehrotra, B., Limaye, S., White, S., Fuchs, A., Lebowicz, Y., Nissel-Horowitz, S., Thomas, A. (2008). EGFR Expression in Gallbladder Carcinoma in North America. International Journal of Medical Sciences, 5(5), 285-291. https://doi.org/10.7150/ijms.5.285.

ACS
Kaufman, M.; Mehrotra, B.; Limaye, S.; White, S.; Fuchs, A.; Lebowicz, Y.; Nissel-Horowitz, S.; Thomas, A. EGFR Expression in Gallbladder Carcinoma in North America. Int. J. Med. Sci. 2008, 5 (5), 285-291. DOI: 10.7150/ijms.5.285.

NLM
Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A. EGFR Expression in Gallbladder Carcinoma in North America. Int J Med Sci 2008; 5(5):285-291. doi:10.7150/ijms.5.285. https://www.medsci.org/v05p0285.htm

CSE
Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A. 2008. EGFR Expression in Gallbladder Carcinoma in North America. Int J Med Sci. 5(5):285-291.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.